Metopirone (Metyrapone)

Metyrapone blocks the enzyme 11‑beta‑hydroxylase (CYP11B1) in the adrenal cortex, preventing the conversion of 11‑deoxycortisol to cortisol. This reduction in cortisol production leads to a rise in ACTH, which can be used diagnostically, and helps lower cortisol levels in conditions such as Cushing's syndrome.

The dosage of Metopirone is individualized and must be determined by a qualified healthcare professional based on the specific indication, severity of disease, and patient characteristics. Prescribers typically start with a low dose and adjust according to clinical response and laboratory monitoring.

Safety data for Metyrapone in pregnancy and lactation are limited. The drug is classified as pregnancy category unknown, and it should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Metopirone. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with alternative agents such as ketoconazole or osilodrostat, Metyrapone offers a more selective inhibition of 11‑beta‑hydroxylase, which can result in fewer hepatic side effects but may cause more pronounced ACTH‑driven mineralocorticoid excess. Choice of therapy depends on patient tolerance, comorbidities, and physician experience.

Metopirone tablets should be stored at ambient temperature below 25 °C, protected from moisture and direct sunlight. Keep the medication in its original container with the lid tightly closed, and store out of reach of children. Do not refrigerate or freeze the tablets.

Metopirone is taken orally, usually with food or a glass of water to reduce gastrointestinal discomfort. The tablets are swallowed whole and should not be chewed, crushed, or split unless specifically instructed by a healthcare provider. Administration timing may be adjusted based on the prescribed dosing schedule.

The most serious adverse reactions include adrenal insufficiency, severe hypertension, electrolyte disturbances such as hypokalemia, and rare cases of hepatic dysfunction or allergic reactions. Patients should be monitored regularly for signs of cortisol deficiency, blood pressure changes, and laboratory abnormalities.

Metopirone is contraindicated in patients with known hypersensitivity to Metyrapone or any tablet excipients. Caution is advised for individuals with uncontrolled hypertension, severe cardiac disease, or active infections, as the drug may exacerbate these conditions. Pregnant or breastfeeding women should only use it when clearly indicated by a physician.